Search for dissertations about: "Parkinson’s disease and L-Dopa treatment"
Showing result 1 - 5 of 45 swedish dissertations containing the words Parkinson’s disease and L-Dopa treatment.
-
1. Dysfunction in the nigrostriatal system : effects of L-DOPA and GDNF
Abstract : Parkinson’s disease is a common neurodegenerative disorder caused by nigrostriatal dopamine loss, with motor deficiencies as the primary outcome. To increase the striatal dopamine content, patients are treated with 3,4-dihydroxyphenyl-l-alanine (l-DOPA). READ MORE
-
2. On dopamine neurons : nerve fiber outgrowth and L-DOPA effects
Abstract : Parkinson’s disease is a disorder mainly characterized by progressive degeneration of dopamine producing neurons in the substantia nigra of the midbrain. The most commonly used treatment strategy is to pharmacologically restore the lost function by the administration of the dopaminergic precursor L-DOPA. READ MORE
-
3. Emerging pharmacotherapies for Parkinson's Disease: Experimental studies in the rat
Abstract : Parkinson´s disease (PD) is a neurodegenerative disorder characterized by the typical motor symptoms, akinesia/bradykinesia, rigidity and resting tremor. These symptoms are caused by a deficiency of dopamine (DA) in the brain, which depends on degeneration of DA neurons in the substantia nigra. READ MORE
-
4. Involvement of non-dopaminergic systems in L-DOPA-induced dyskinsia
Abstract : Parkinson's disease and L-DOPA-induced dyskinesia (LID) does not merely involve the dopamine (DA) system but also include non-dopaminergic systems such as glutamate and serotonin (5-HT). An aberrant glutamate transmission at the corticostriatal synapse, has been linked to LID. READ MORE
-
5. Microdialysis as a Tool in Studies of L-Dopa and Metabolites in Malignant Melanoma and Parkinson’s Disease
Abstract : A model with human melanoma xenografts transplanted to athymic mice has been adopted for in vivo studies of 5-S-cysteinyldopa (an intermediate pigment metabolite), glutathione, and cysteine. L-Dopa is an intermediate metabolite in pigment formation and is also important in the treatment of Parkinson's disease, and therefore 1 have also studied the pharmacokinetics of this compound. READ MORE